Search results
Results from the WOW.Com Content Network
This is a list of chemotherapeutic agents, also known as cytotoxic agents or cytostatic drugs, that are known to be of use in chemotherapy for cancer.This list is organized by type of agent, although the subsections are not necessarily definitive and are subject to revision.
1. Cytotoxic antineoplastics: 1.01 Nucleoside analogues: Azacitidine: SC, IV: DNA methyltransferase inhibitor and incorporates itself into RNA, hence inhibiting gene expression. [6] Myelodysplastic syndromes, acute myeloid leukaemia and chronic myeloid leukaemia: Myelosuppression, kidney failure (uncommon/rare), renal tubular acidosis and ...
Researchers can either look for cytotoxic compounds, if they are interested in developing a therapeutic that targets rapidly dividing cancer cells, for instance; or they can screen "hits" from initial high-throughput drug screens for unwanted cytotoxic effects before investing in their development as a pharmaceutical. [3]
Other drugs used to treat myeloma such as lenalidomide have shown promise in treating AL amyloidosis. [173] Chemotherapy drugs are also used in conditioning regimens prior to bone marrow transplant (hematopoietic stem cell transplant). Conditioning regimens are used to suppress the recipient's immune system in order to allow a transplant to ...
Trastuzumab emtansine is an antibody-drug conjugate (ADC), a combination between a monoclonal antibody and a small-molecule drug. Each molecule of trastuzumab emtansine consists of a single trastuzumab molecule with several molecules of DM1, a cytotoxic maytansinoid, attached. [21]
Bisantrene's cardioprotective mechanism of action is important because "15 of the 35 commercially available anti-cancer drugs have direct cardiotoxic effects on HCM (human cardiomyocytes)." [ 9 ] According to the Australian Cardiovascular Alliance Cardio-Oncology Working Group , a drug which is simultaneously anticancer and cardioprotective is ...
SRI International and the La Jolla Cancer Research Foundation (now the Sanford-Burnham Medical Research Institute) collaborated on work that resulted in patent filings for the drug. [ 17 ] The developer of bexarotene (brand name Targretin) was Ligand Pharmaceuticals , a San Diego biotech company which received FDA approval for the drug in 1999 ...
SN-38 is an antineoplastic drug. It is the active metabolite of irinotecan (an analog of camptothecin - a topoisomerase I inhibitor) but has 1000 times more activity than irinotecan itself. In vitro cytotoxicity assays show that the potency of SN-38 relative to irinotecan varies from 2- to 2000-fold.